Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 783 | 100 | 672 |
| Samples | 400 | 61 | 333 |
| Peptides | 297 | 45 | 256 |
Function
F2 · Coagulation factor II, thrombin
This gene encodes the prothrombin protein (also known as coagulation factor II). This protein is proteolytically cleaved in multiple steps to form the activated serine protease thrombin. The activated thrombin enzyme plays an important role in thrombosis and hemostasis by converting fibrinogen to fibrin during blood clot formation, by stimulating platelet aggregation, and by activating additional coagulation factors. Thrombin also plays a role in cell proliferation, tissue repair, and angiogenesis as well as maintaining vascular integrity during development and postnatal life. Peptides derived from the C-terminus of this protein have antimicrobial activity against E. coli and P. aeruginosa. Mutations in this gene lead to various forms of thrombosis and dysprothrombinemia. Rapid increases in cytokine levels following coronavirus infections can dysregulate the coagulation cascade and produce thrombosis, compromised blood supply, and organ failure. [provided by RefSeq, May 2020].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 287 amino-acid changes on canonical ENST00000311907 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in F2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in F2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 17/612 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Melanoma | 1/210 0% | 51/1899 3% |
| Colorectal Carcinoma | 8/143 6% | 59/3239 2% |
| Rhabdomyosarcoma | 0/33 0% | 4/171 2% |
| Gastric Carcinoma | 3/74 4% | 33/1809 2% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 24/1390 2% |
| Cervical Carcinoma | 2/35 6% | 5/422 1% |
| Other Solid Cancers | 0/94 0% | 19/1515 1% |
| Glioma | 1/52 2% | 21/2127 1% |
| Neuroendocrine Tumour | 3/154 2% | 4/577 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 4/810 0% |
| Ovarian Carcinoma | 4/109 4% | 6/998 1% |
| Head and Neck Carcinoma | 0/85 0% | 10/1574 1% |
| Biliary Tract Carcinoma | 3/54 6% | 3/950 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 9/1592 1% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Bladder Carcinoma | 1/58 2% | 4/956 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Breast Carcinoma | 7/144 5% | 7/3264 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Pancreatic Carcinoma | 1/89 1% | 5/1611 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 8/2550 0% |
Mutation Distribution
Where F2 is mutated · all tissues, split by cell line vs tissue
How many mutations in F2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 783 mutations in F2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|